Copyright (c) 2024 Revista médico científica
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Background: In 1931, Sampson was the first to describe the term peritoneal carcinomatosis to refer to the peritoneal spread of an advanced ovarian neoplasm. Today, it encompasses all tumor spread, massive or regional, involving the peritoneal serosa and adjacent anatomical structures. About 10% of patients with colorectal carcinoma present peritoneal carcinomatosis at the time of diagnosis. In addition, 10% to 35% of patients with recurrence will present lesions exclusively at the peritoneal level. In more than half of these patients the peritoneum is the first and only site of metastasis.
Objective: To present the published evidence on the approach and surgical treatment of peritoneal carcinomatosis of colorectal cancer in other latitudes and how its implementation could offer a promising panorama for the quality of life of these patients in Panama.
Design: We used scientific articles indexed between 2010 and 2020 that were selected for their relevance, validity and quality of content, such as those available at the National Center for Biotechnology Information, Surgical Oncology Clinics of North America, Annals of Surgical Oncology, World Journal of Surgical Oncology, obtained through various virtual libraries.
Conclusion: Cytoreductive surgery in combination with intraperitoneal hyperthermal chemotherapy has improved overall 5-year survival from 40% to 51%, giving promising results in patients with highly selected peritoneal carcinomatosis of colorectal origin; it is even considered the only potentially curative treatment.
